SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Discussion centers on Midnights mainnet launch and reported Coinbase listing, with traders also highlighting Google Cloud and Vodafone validator participation as signs of growing reach. Supporters see adoption momentum, while skeptics point to ongoing token-selling pressure and question whether the developments will translate into sustained demand.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs spectrum acquisition and Starlink Mobile plans to become a wireless carrier have fueled concern that T-Mobile could face greater long-term competition, contributing to a sharp selloff in telecom stocks. Traders are divided between viewing SpaceX as a future threat and calling the reaction excessive because building a competitive terrestrial network would require substantial investment and time.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cashs sharp rallies and pullbacks are driving the discussion, with traders citing CME futures access and a Grayscale filing as possible catalysts for an earlier breakout. Bulls point to BCHs relative strength and the planned CashVM upgrade, while skeptics question its utility and warn that momentum could fade.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs high-volume rally is being linked to anticipation of founder Patrick Soon-Shiongs Piper Sandler oncology symposium chat, where he is expected to discuss trial progress; traders are also watching for updates on bladder-cancer programs and international expansion. Some bullish posts speculate about a partnership or short squeeze, but those claims remain unverified.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

IOVAs rally is drawing attention amid the companys higher revenue outlook and expectations for upcoming melanoma, sarcoma and lung-cancer updates. Traders also point to a reported decline in short interest as a possible source of buying pressure, while others warn that the sharp run-up could give way to volatility and debate whether the NSCLC update will arrive on schedule.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is drawing attention amid weak price performance and concerns about exchange delistings, with traders debating whether the listing changes are materially bearish or being overstated. Bulls point to JasmyChain activity and ecosystem developments as potential sources of utility, while critics question whether meaningful adoption has emerged.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorillas non-binding plan to acquire its first U.S. data center and expand its AI infrastructure footprint is drawing attention. Some traders view the move as strategic growth, while many question how it will be financed and whether the company can execute, with those concerns accompanying the selloff.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is being linked to its Nasdaq-100 reentry and resulting index-fund buying, as well as optimism around the NIHs planned cancer-vaccine initiative and the companys personalized cancer-vaccine program with Merck. Bulls see potential in the oncology pipeline, while skeptics question the valuation and profitability and attribute part of the move to index flows or short covering.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Traders are focused on the planned AerodromeVelodrome merger and expansion of the unified Aero protocol beyond Base to Ethereum and other chains, which they see as a potential source of broader liquidity and fee growth. Sentiment is largely bullish around a breakout toward the $1 level, though some question the rollout timing and warn that emissions or sell-the-news activity could weigh on the token.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

The DOJs clearance of Transoceans planned all-stock Valaris merger is a key focus, alongside new contract awards that add to backlog. Traders see potential synergies and elevated short interest as bullish, while others are frustrated by the muted share response and cite debt, dilution, and continued selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.read more...

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

GT Biopharma says AI-driven drug discovery tools are accelerating pipeline development and may yield new pre-IND candidates by 2027.read more...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic PR Newswire SAN FRANCISCO, May 18, 2026 Issued on behalf of GT Biopharma, Inc.SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.read more...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE and Dual Targeting TriKE platforms. Its product candidates include GTB-3650, a CD33-targeted therapy for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, and GTB-5550, a B7-H3-targeted therapy for solid tumors. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$6.68
Prev Close	$5.96
Open	$5.96
Dividend Yield	0.00%
50-Day Moving Average	$7.19
Beta	0.88
Avg. Volume	120,815.85
PE Ratio	-0.07

52-Week High	$28.75
52-Week Low	$4.91
Market Capitalization	$12.28M
EPS (Annual)	-$156.21
Price to Book	3.35
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GTBP Fundamentals